Monoclonal Antibodies for the Prevention and Treatment of COVID-19

Internet Enduring Material sponsored by the Stanford University School of Medicine. Presented by the Department of Medicine at the Stanford University School of Medicine.

This presentation discusses: Monoclonal Antibodies for the Prevention and Treatment of COVID-19. Topics include: Clinical trials and Phase 2 studies. the use of antibody therapy to treat viral infections, how they have been used for a long time, including for the treatment of influenza and SARS 1 and 2. Discussed advantages of mAbs compared with other drugs. Discussed antibody protection develops in nearly all patients with symptomatic COVID-19. Pre-clinical data have identified highly potent neutralizing mAbs and several synergistic mAb combinations. Nearly all mAbs target the RBD and most target ACE2-binding residues. mAbs that cross-neutralize SARS-CoV may protect against other SARS-related C0Vs but are generally less potent against SARS-CoV-2. Most mAbs require minimal affinity maturation explaining why they develop so often, albeit at relatively low levels, among infected persons and in those receiving vaccines. Potent neutralizing mAbs have been consistently protective in animal model challenge studies. Also discussed 3 mAbs that are in phase III trials. Nine additional mAbs are in phase 1 trials and ten more will soon begin phase 1 trials.

  Release Date: October 5, 2020
  Expiration Date: October 5, 2021
  Estimated Time to Complete: 24 minutes
  CME Credits Offered: 0.5
  Registration Fee: FREE

1. Analyze pre-clinical and phase 2 study data to determine the effectiveness of monoclonal antibodies for the prevention and treatment of SARS-C0V-2 infections.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

American Medical Association (AMA)
Stanford Medicine designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. 

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: http://lane.stanford.edu/portals/cultural.html

Reference/Bibliography List
COVID-19 CME Resources https://med.stanford.edu/cme/COVID19.html

The Stanford University School of Medicine adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education.   There are no relevant financial relationships with ACCME-defined commercial interests for anyone who was in control of the content of this activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Robert William Shafer, MD
Professor of Medicine - Infectious Diseases
Stanford University School of Medicine

Faculty